South Africa’s healthcare discourse is often dominated by innovation: new treatments, breakthrough therapies, digital platforms, and the evolving potential of biosimilars and generics. But beneath these advancements lies an issue that is far less glamorous, one that rarely makes headlines but ultimately determines whether any of these innovations reach the patient at all: infrastructure.
Whether you are in a bustling metro hospital or a rural clinic deep in Limpopo, access to medicine isn’t just about policy or procurement, it’s about whether systems, people, and physical logistics are equipped to deliver consistently and effectively.
We can’t keep talking about health equity without acknowledging the conditions of many of our clinics and distribution points. Broken refrigeration units, intermittent electricity, stock locked in depots due to a lack of transport, or medicine that never arrives because the last mile delivery partner wasn’t paid on time, these are all real, recurring barriers. And they don’t just result in inconvenience; they directly translate to delayed treatment, worsened outcomes, and in some cases, avoidable loss of life.
Let’s take something as routine as hypertension management. Patients with high blood pressure rely on regular medication to prevent strokes or heart attacks. If a clinic has no stock due to a supply chain delay, or if the only pharmacist on duty is off sick and there is no backup, those patients may go weeks without medication. Now scale that across hundreds of facilities and thousands of patients. What we get is not a health system, but a lottery.
For too long, the infrastructure challenges in healthcare have been treated as “operational” issues instead of core components of access. Procurement backlogs? That’s access. Unpaid suppliers halting deliveries? Also access. Clinics without temperature control for insulin or vaccines? Still access. The minute any of these break down, so does our ability to provide care.
And yet, most health conversations in policy circles remain abstract. We talk about reform and universal coverage and market entry, but not enough about the people responsible for receiving, storing, and dispensing medicine. The pharmacy assistant at a community clinic is just as critical to the system as the regulatory authority issuing approvals.
The infrastructure conversation also includes digital capacity. How many clinics still use paper stock cards to manage medicine inventory? How many rely on phone calls to district offices when there is a stockout, instead of real time, integrated supply tracking? It is hard to manage what you can’t measure, and even harder when your measurement tools are two steps behind modern systems.
Of course, there are bright spots. Pilot projects using stock visibility apps, public-private logistics collaborations, and community health worker support programmes have shown what is possible when infrastructure and innovation go hand in hand. But these examples remain the exception, not the rule.
This matters even more now, as the country looks toward implementing National Health Insurance (NHI). A system built to deliver equitable access on a national scale cannot be built on crumbling logistics or overburdened infrastructure. Expanding benefits and broadening formularies won’t help if the medication can’t reliably make it to the clinic shelf.
It’s time to start reframing what we mean when we talk about access. It is not just about what medicine is registered, or what it costs. It is about whether the infrastructure exists to get that medicine, consistently, into the hands of the people who need it most. That includes warehousing, cold chains, trained personnel, reliable transport, and yes, budgets that are actually paid on time.
If we want to create a resilient, equitable healthcare system, infrastructure must be a first order issue, not an afterthought. Policymakers, health economists, and development partners need to start valuing the “unseen” parts of the access chain just as much as the visible ones. Because at the end of the day, a breakthrough treatment is only a breakthrough if someone actually receives it.